Category: Media Release

Race Oncology Limited (ASX:RAC) is an Australian pharmaceutical company focused on the development of its key drug, Zantrene, which is currently being studied for pre-clinical and clinical efficacy in several cancer indications. Zantrene is a highly targeted precision oncology agent…

Race Oncology June 2022 Quarterly Investor Briefing

Race Oncology CEO Phillip Lynch and CSO Dr Daniel Tillett present Race’s June 2022 Quarterly Investor Briefing followed by a Q&A session.

30 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results from our preclinical cardioprotection program in collaboration with researchers from the University of Newcastle (ASX announcement: 28 April 2021). This program aimed at exploring the…